comparemela.com

Page 3 - Multicenter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How to achieve a functional cure for chronic hepatitis B

How to achieve a functional cure for chronic hepatitis B
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Oramed Pharmaceuticals Inc Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial comparing the efficacy of ORMD-0801 to placebo in. | January 12, 2023

Is immediate postabortal insertion of intrauterine devices safe? Study clarifies

SWEDEN: When compared to installation two to four weeks following an abortion, inserting an IUD within 48 hours of a complete abortion seemed safe and was linked to reduced pain scores, states a study.

Dompe Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia. Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy MILAN, June 13, 2022 /PRNewswire/ Dompe farmaceutici S.p.A ("Dompe") today announcedresults from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 Internati

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.